长江生命科技李泽钜:买股票纯为收息没理由投资生物科技行业

阿斯达克财经
May 22, 2025

长江生命科技(00775.HK) 主席李泽钜于股东会后被问到对公司前景看法,他指生物科技(Biotech)研究是高回报、高风险的行业。如果成功研究,单一产品的价值有机会高过很多上市的基建、甚至地产公司,但如果不成功亦没话可说,因此他认为如果买股票纯粹为收息,没理由投资于生物科技行业,但如果有全面的投资组合,将一部分资金投放于这类高值博率投资上是正确的。被问到是否考虑将生物制药部门剥离,并根据香港第...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10